ArticleClinical rheumatology2007
Quantitative salivary gland scintigraphy can distinguish patients with primary Sjøgren's syndrome during the evaluation of sicca symptoms.
Article in Clinical rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 41 citations in OpenAlex.
- Correlations between salivary gland scintigraphy and histopathologic data of salivary glands in patients with primary Sjogren's syndrome.Clinical rheumatology · 2022Article
- The validity of salivary gland scintigraphy in Sjögren's syndrome diagnosis: comparison of visual and excretion fraction analyses.Clinical rheumatology · 2021Article
- Semi-quantitative analysis of salivary gland scintigraphy in Sjögren's syndrome diagnosis: a first-line tool.Clinical oral investigations · 2017Article
- Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.Thyroid : official journal of the American Thyroid Association · 2013Article
- Semi-quantitative evaluation of salivary gland function in Sjögren's syndrome using salivary gland scintigraphy.Clinical rheumatology · 2012Article
- [Interdisciplinary point of contact between rheumatology and pneumology].Zeitschrift fur Rheumatologie · 2008Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal findings on salivary gland scintigraphy (SGS) are part of the classification criteria for Sjøgren's syndrome (SS), but SGS is operator dependent and poorly standardised. We studied the use of quantitative data on the uptake, concentration and excretion of the four major salivary glands in the evaluation of sicca patients. During an initial clinical evaluation for sicca symptoms (mean duration, 51 months), 24 subjects were classified as either SS (n = 8) or isolated sicca (IS; n = 16). SGS was then performed after i.v. injection of 200 MBq pertecnetat. Digitalised quantitative data on time-to-peak uptake (Tmax), peak tracer distribution (C%) and stimulated excretion (E%) were calculated from time-activity curves and compared between groups and controls (n = 8) and correlated to clinical data. Statistical analysis was performed with non-parametric tests. SS patients had longer Tmax in both parotic glands (18.1 min; p < 0.01)) and both submandibular glands (mean 13.7 min, p < 0.05); whereas Tmax in IS patients was similar as in controls in both parotic (10.4 min; p > 0.2) and submandibular glands (9.4 min; p > 0.4). C% was significantly lower in the parotic glands of both the SS and the IS group compared to the controls (p < 0.01). E% was significantly reduced in SS patients (16.3% for parotic and 17.4% for submandibular glands; p < 0.01); whereas in the IS patients, excretion (32, 2% for parotic and 26, 9% for submandibular glands) was similar from all glands as in the control groups (35, 2% for parotic and 27, 8% for submandibular glands). No correlation was found between these SGS results and age, focus score, erythrocyte sedimentation rate, serum creatinin or immunoglobulin levels. No IS patient progressed to full-blown pSS during the 4 years of follow-up. Quantitative SGS data are useful and objective tools to distinguish patients with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.